PharmaSeq

Home Company News & Events Press Releases 2015 PharmaSeq Announces Publication of Key Paper on Prostate Cancer Diagnostics

Press Releases

PharmaSeq Announces Publication of Key Paper on Prostate Cancer Diagnostics

Monmouth Junction, NJ, April 8, 2015. PharmaSeq, Inc., announced today the publication of an important paper on an improved method for prostate cancer (PCa) diagnostics. The paper, published in PLOS ONE, is titled “Macrophage Inhibitory Cytokine 1 Biomarker Serum Immunoassay in Combination with PSA Is a More Specific Diagnostic Tool for Detection of Prostate Cancer” and is authored by scientists at PharmaSeq and the Brady Institute of Urological Studies at The Johns Hopkins University School of Medicine in Baltimore, MD.

Prostate cancer is the most common malignancy affecting men in the U.S. Current accepted practice for diagnosing the possibility of PCa is to use the prostate-specific antigen (PSA) test. The PSA test, although it has high sensitivity for the disease, exhibits low specificity that frequently leads to over-diagnosis and over-treatment, including biopsies that usually confirm false positives and can lead to further medical complications. In the PLOS ONE study, macrophage inhibitory cytokine 1 (MIC-1) levels were determined on an assay configured on PharmaSeq’s patented p-Chips®, which are small integrated circuits that store in their memories an ID number identifying the antibody probe for the biomarkers attached to their surfaces. The study concluded that “the correlation of MIC-1 levels along with PSA concentrations in serum improves the specificity of PCa diagnosis without compromising the high sensitivity of the PSA test alone.” The authors add that combining PSA and MIC-1 levels has potential for patient therapy strategies.

Wlodek Mandecki, Ph.D., President and Chief Scientific Officer of PharmaSeq, commented, “This study, which is one of several that have been completed with our colleagues at The Johns Hopkins University School of Medicine, is important and we believe will lead to improvements both in diagnosis of prostate cancer and improved methods for monitoring during treatment. He adds, “The work also confirms the value of methods that PharmaSeq has developed for performing highly sensitive diagnostic assays on p-Chips using silver nanofilm technology to increase sensitivity for analytes. We predict that the platform will find great utility in other multiplex protein biomarker assays.”

About PharmaSeq. PharmaSeq, Inc., has developed an ultra-small microtransponder tag called the p-Chip that is poised to revolutionize several billion-dollar industries. The p-Chip is a fundamental platform that can be combined with either nucleic acid or antibody probes to construct highly sensitive assays for cancer and infectious disease testing. The same technology can be used to perform sequence-directed or split-and-pool chemical synthesis for constructing nucleic acid and peptide libraries. p-Chips are the smallest, most technologically advanced commercial product available today for tagging and authenticating consumer goods, industrial goods and small animals. Find us on the web at www.pharmaseq.com.

For further information, please contact Richard G. Morris, Ph.D., CEO, at (732) 355-0100. 

PharmaSeq, Inc.
11 Deer Park Drive, Suite 104
Monmouth Junction, NJ 08852
Find us on the web at: www.pharmaseq.com.

 


Home Company News & Events Press Releases 2015 PharmaSeq Announces Publication of Key Paper on Prostate Cancer Diagnostics